Education
About Us
Working with TipRanks
Follow Us
Lexicon Pharmaceuticals (LXRX)
NASDAQ:LXRX
LXRX Stock Chart & Stats
$1.21
-$0.12(-12.49%)
At close: 4:00 PM EST
$1.21
-$0.12(-12.49%)
Day’s Range― - ―
52-Week Range$0.28 - $1.66
Previous CloseN/A
Volume2.02M
Average Volume (3M)1.77M
Market Cap
$443.35M
Enterprise Value$439.58M
Total Cash (Recent Filing)$115.95M
Total Debt (Recent Filing)$58.15M
Price to Earnings (P/E)―
Beta2.14
Next Earnings
Mar 18, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding363,398,680
10 Day Avg. Volume1,803,281
30 Day Avg. Volume1,773,513
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.62
Price to Sales (P/S)7.60
P/FCF Ratio-1.31
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue6.20
Enterprise Value/Gross Profit9.84
Enterprise Value/Ebitda-9.10
Forecast
1Y Price Target
$3.97Price Target Upside228.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.17
Revenue Forecast (FY)$44.87M
Bulls Say, Bears Say
Bulls Say
Financial StabilityThe company has a cash runway that extends deep into 2026, providing financial stability for ongoing projects.
Partnership PotentialA potential pain partnership for pilavapadin in DPNP could lead to a meaningful rerating of the stock.
Regulatory MilestonesManagement highlighted upcoming milestones, including potential approval of Zynquista in T1D, contingent on NDA resubmission, which could positively impact the stock.
Bears Say
Regulatory ConcernsConcerns from the FDA around Zynquista revolve around diabetic ketoacidosis rates.
Treatment AdherenceParticipants in the 20 mg arm were the least adherent, potentially driven by increased adverse events and treatment discontinuations leading to lack of responses.
Lexicon Pharmaceuticals News
LXRX FAQ
What was Lexicon Pharmaceuticals’s price range in the past 12 months?
Lexicon Pharmaceuticals lowest stock price was $0.28 and its highest was $1.66 in the past 12 months.
What is Lexicon Pharmaceuticals’s market cap?
Lexicon Pharmaceuticals’s market cap is $443.35M.
When is Lexicon Pharmaceuticals’s upcoming earnings report date?
Lexicon Pharmaceuticals’s upcoming earnings report date is Mar 18, 2026 which is in 84 days.
How were Lexicon Pharmaceuticals’s earnings last quarter?
Lexicon Pharmaceuticals released its earnings results on Nov 06, 2025. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.066 by $0.026.
Is Lexicon Pharmaceuticals overvalued?
According to Wall Street analysts Lexicon Pharmaceuticals’s price is currently Undervalued.
Does Lexicon Pharmaceuticals pay dividends?
Lexicon Pharmaceuticals does not currently pay dividends.
What is Lexicon Pharmaceuticals’s EPS estimate?
Lexicon Pharmaceuticals’s EPS estimate is -0.07.
How many shares outstanding does Lexicon Pharmaceuticals have?
Lexicon Pharmaceuticals has 363,398,680 shares outstanding.
What happened to Lexicon Pharmaceuticals’s price movement after its last earnings report?
Lexicon Pharmaceuticals reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.066. Following the earnings report the stock price went up 3.623%.
Which hedge fund is a major shareholder of Lexicon Pharmaceuticals?
Currently, no hedge funds are holding shares in LXRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lexicon Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.97 (228.10% Upside)
$3.97 (228.10% Upside)
Blogger Sentiment
Bullish
LXRX Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 229.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 6.8%
Last 30 Days ▲ 6.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
46.31%
12-Months-Change
Fundamentals
Return on Equity
-45.92%
Trailing 12-Months
Asset Growth
-35.87%
Trailing 12-Months
Company Description
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
LXRX Company Deck
LXRX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive progress in revenues, R&D advancements, and strategic partnerships, while also highlighting challenges such as decreased cash reserves and the need for FDA feedback for key products. Overall, the positive aspects of the company's progress and strategic focus on future opportunities suggest a cautiously optimistic outlook.View all LXRX earnings summariesLXRX Stock 12 Month Forecast
Average Price Target
$3.97
▲(228.10% Upside)
Technical Analysis
Ownership Overview
13.05% Insiders
8.75% Mutual Funds
49.95% Other Institutional Investors
25.39% Public Companies and
Individual Investors